
Richter Applies for Authorization of Drug Suitable for Treatment of COVID-19
Gedeon Richter’s headquarters in Budapest Gedeon Richter Plc. has submitted a marketing authorization application (MAA) to the European Medicines Agency for its proposed biosimilar to RoActemra® tocilizumab (RGB-19), the Budapest-based pharmaceutical …